IN2014MN01547A - - Google Patents
Info
- Publication number
- IN2014MN01547A IN2014MN01547A IN1547MUN2014A IN2014MN01547A IN 2014MN01547 A IN2014MN01547 A IN 2014MN01547A IN 1547MUN2014 A IN1547MUN2014 A IN 1547MUN2014A IN 2014MN01547 A IN2014MN01547 A IN 2014MN01547A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disclosed
- methods
- agents
- host
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1547MUN2014 IN2014MN01547A (de) | 2012-02-10 | 2013-02-08 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN147KO2012 | 2012-02-10 | ||
| IN1017KO2012 | 2012-09-04 | ||
| IN1547MUN2014 IN2014MN01547A (de) | 2012-02-10 | 2013-02-08 | |
| PCT/IB2013/051062 WO2013118097A1 (en) | 2012-02-10 | 2013-02-08 | Antiviral compounds with a dibenzooxaheterocycle moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01547A true IN2014MN01547A (de) | 2015-05-08 |
Family
ID=54259033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1547MUN2014 IN2014MN01547A (de) | 2012-02-10 | 2013-02-08 | |
| IN1548MUN2014 IN2014MN01548A (de) | 2012-02-10 | 2013-02-09 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1548MUN2014 IN2014MN01548A (de) | 2012-02-10 | 2013-02-09 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9073943B2 (de) |
| EP (2) | EP2812326A1 (de) |
| JP (1) | JP6034883B2 (de) |
| KR (1) | KR20140129034A (de) |
| CN (1) | CN104136433B (de) |
| AU (2) | AU2013217224B2 (de) |
| BR (1) | BR112014019584A8 (de) |
| CA (2) | CA2862755A1 (de) |
| IN (2) | IN2014MN01547A (de) |
| MX (1) | MX2014009546A (de) |
| NZ (2) | NZ628515A (de) |
| SG (2) | SG11201404475TA (de) |
| WO (2) | WO2013118097A1 (de) |
| ZA (1) | ZA201405490B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841095A1 (en) | 2011-07-09 | 2013-01-17 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis c virus inhibitors |
| IN2014MN01547A (de) | 2012-02-10 | 2015-05-08 | Lupin Ltd | |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| CN104725365B (zh) * | 2013-12-23 | 2019-02-26 | 南京圣和药业股份有限公司 | 丙型肝炎病毒抑制剂及其应用 |
| WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| KR102794564B1 (ko) * | 2016-04-08 | 2025-04-15 | 듀폰스페셜티머터리얼스코리아 유한회사 | 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| ES3046711T3 (en) | 2016-04-15 | 2025-12-02 | Beckman Coulter Inc | Photoactive macromolecules and uses thereof |
| EP4483875A3 (de) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclische degronimere für zielproteinabbau |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3455219A4 (de) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Amingebundene c3-glutarimiddegronimere für zielproteinabbau |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3641762B1 (de) | 2017-06-20 | 2026-02-18 | C4 Therapeutics, Inc. | N/o-gebundene degrone und degronimere zum proteinabbau |
| UY38705A (es) * | 2019-05-23 | 2020-12-31 | Irbm S P A | Inhibidores tricíclicos sustituidos con oxalamido del virus de hepatitis b |
| CN114605310B (zh) * | 2022-04-09 | 2024-05-07 | 都创(上海)医药科技股份有限公司 | 一种氮杂五元环并三元环羧酸酯衍生物及其盐的合成方法 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO2004014852A2 (en) | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
| EP1650202A4 (de) | 2003-07-31 | 2007-04-04 | Taisho Pharmaceutical Co Ltd | 4,5-dihydronaphtho[1,2-b]thiophenderivat |
| HUE028213T2 (en) | 2003-09-19 | 2016-12-28 | Janssen Pharmaceutica Nv | 4 - ((Phenoxyalkyl) thio) -phenoxyacetic acid for use in the treatment of PPAR-delta-mediated conditions |
| DE602004008959T2 (de) | 2003-11-07 | 2008-06-19 | F. Hoffmann-La Roche Ag | Benzoäbüä1,4üdioxepinderivate |
| GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
| GB0501964D0 (en) | 2005-01-31 | 2005-03-09 | Arrow Therapeutics Ltd | Chemical compounds |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| AU2006290442B2 (en) | 2005-09-16 | 2010-07-29 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis C |
| JP2009519342A (ja) | 2005-12-12 | 2009-05-14 | ジェネラブズ テクノロジーズ インコーポレーティッド | Ｎ−（６員芳香環）−アミド抗ウイルス化合物 |
| RU2008128453A (ru) | 2005-12-12 | 2010-01-20 | Дженелабс Текнолоджис, Инк. (Us) | Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения |
| WO2007082554A1 (en) | 2006-01-23 | 2007-07-26 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Modulators of hcv replication |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7923004B2 (en) | 2006-10-13 | 2011-04-12 | Xtl Biopharmaceuticals Ltd. | 4-ethynyl pyrazole derivative compounds and methods for treatment of HCV |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010510246A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | アミド抗ウイルス化合物 |
| US20100055071A1 (en) | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20090317360A1 (en) | 2007-06-12 | 2009-12-24 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
| SI2170888T1 (sl) | 2007-06-29 | 2015-10-30 | Gilead Sciences, Inc. | Purinski derivati in njihova uporaba kot modulatorjev receptorja tipa toll-7 |
| US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7728027B2 (en) | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| WO2009034390A1 (en) | 2007-09-14 | 2009-03-19 | Arrow Therapeutics Limited | Heterocyclic derivatives and their use in treating hepatitis c |
| BRPI0817881A2 (pt) | 2007-10-10 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
| KR20100123717A (ko) | 2008-02-12 | 2010-11-24 | 브리스톨-마이어스 스큅 컴퍼니 | Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체 |
| HRP20120440T1 (hr) | 2008-02-12 | 2012-06-30 | Bristol-Myers Squibb Company | Inhibitori virusa hepatitisa c |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8147818B2 (en) | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL2242752T3 (pl) | 2008-02-13 | 2012-12-31 | Bristol Myers Squibb Co | Imidazolilobifenyloimidazole jako inhibitory wirusa zapalenia wątroby typu c |
| HRP20130048T1 (hr) | 2008-04-23 | 2013-02-28 | Gilead Sciences, Inc. | Karba-nukleozidni analozi za antivirusnu terapiju |
| US8133884B2 (en) | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20110217265A1 (en) | 2008-09-23 | 2011-09-08 | Glenn Jeffrey S | Screening for Inhibitors of HCV Amphipathic Helix (AH) Function |
| EP2774927A1 (de) * | 2008-12-03 | 2014-09-10 | Presidio Pharmaceuticals, Inc. | HCV-NS5A-Hemmer |
| CA2751277C (en) | 2009-02-10 | 2018-10-30 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| WO2010096462A1 (en) | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | Ｃ型肝炎病毒抑制劑 |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| CN102427729B (zh) | 2009-03-27 | 2014-09-03 | 默沙东公司 | 丙型肝炎病毒复制的抑制剂 |
| US8709999B2 (en) | 2009-03-27 | 2014-04-29 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic HCV inhibitors |
| MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
| US20110237636A1 (en) | 2009-03-30 | 2011-09-29 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| RS56654B8 (sr) | 2009-05-13 | 2021-06-30 | Gilead Pharmasset Llc | Antiviralna jedinjenja |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2010148006A1 (en) | 2009-06-16 | 2010-12-23 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| CA2768637A1 (en) | 2009-08-07 | 2011-02-10 | Tibotec Pharmaceuticals | Phenyl ethynyl derivatives as hepatitis c virus inhibitors |
| EP2475254A4 (de) | 2009-09-11 | 2013-05-22 | Enanta Pharm Inc | Hemmer des hepatitis-c-virus |
| US9156818B2 (en) | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8415374B2 (en) | 2009-10-12 | 2013-04-09 | Bristol-Myers Squibb Company | Combinations of hepatitis C virus inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2785488A1 (en) | 2009-12-22 | 2011-07-21 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| US20130072523A1 (en) | 2009-12-24 | 2013-03-21 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of flavivirus infections |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| AR080433A1 (es) | 2010-03-02 | 2012-04-11 | Merck Sharp & Dohme | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. |
| CN102858157A (zh) | 2010-03-04 | 2013-01-02 | 埃南塔制药公司 | 作为hcv复制的抑制剂的组合药物活性剂 |
| EP2545060B1 (de) | 2010-03-09 | 2015-11-25 | Merck Sharp & Dohme Corp. | Kondensierte tricyclische silylverbindngen und verfahren zu deren verwendung zur behandlung von viralen krankheiten |
| WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2011151652A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
| WO2011151651A1 (en) | 2010-06-03 | 2011-12-08 | Arrow Therapeutics Limited | Benzodiazepine compounds useful for the treatment of hepatitis c |
| US8778938B2 (en) | 2010-06-04 | 2014-07-15 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| TW201201801A (en) | 2010-06-09 | 2012-01-16 | Presidio Pharmaceuticals Inc | Inhibitors of HCV NS5A protein |
| WO2012018534A2 (en) | 2010-07-26 | 2012-02-09 | Schering Corporation | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| MX337936B (es) | 2010-08-04 | 2016-03-29 | Bristol Myers Squibb Co | Compuestos inhibidores del virus de la hepatitis c. |
| US20120195857A1 (en) | 2010-08-12 | 2012-08-02 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| EP2603080A4 (de) | 2010-08-12 | 2014-01-22 | Enanta Pharm Inc | Hemmer des hepatitis-c-virus |
| MX2013001869A (es) | 2010-08-17 | 2013-06-28 | Vertex Pharma | Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae. |
| CA2812699A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| BR112013007696A2 (pt) | 2010-09-29 | 2019-09-24 | Merck Sharp & Dohme | composto, composição farmacêutica, usos do referido composto e da referida composição |
| WO2012041227A1 (en) | 2010-09-29 | 2012-04-05 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds for treating hepatitis c viral infection |
| WO2012068234A2 (en) | 2010-11-17 | 2012-05-24 | Gilead Sciences, Inc. | Antiviral compounds |
| IN2014MN01547A (de) | 2012-02-10 | 2015-05-08 | Lupin Ltd |
-
2013
- 2013-02-08 IN IN1547MUN2014 patent/IN2014MN01547A/en unknown
- 2013-02-08 EP EP13715002.5A patent/EP2812326A1/de not_active Ceased
- 2013-02-08 SG SG11201404475TA patent/SG11201404475TA/en unknown
- 2013-02-08 NZ NZ628515A patent/NZ628515A/en not_active IP Right Cessation
- 2013-02-08 CA CA2862755A patent/CA2862755A1/en not_active Abandoned
- 2013-02-08 AU AU2013217224A patent/AU2013217224B2/en not_active Expired - Fee Related
- 2013-02-08 WO PCT/IB2013/051062 patent/WO2013118097A1/en not_active Ceased
- 2013-02-08 US US14/375,534 patent/US9073943B2/en not_active Expired - Fee Related
- 2013-02-09 JP JP2014556185A patent/JP6034883B2/ja not_active Expired - Fee Related
- 2013-02-09 CN CN201380008883.4A patent/CN104136433B/zh not_active Expired - Fee Related
- 2013-02-09 EP EP13708912.4A patent/EP2812327A1/de not_active Withdrawn
- 2013-02-09 SG SG11201404365SA patent/SG11201404365SA/en unknown
- 2013-02-09 US US14/375,530 patent/US9073942B2/en not_active Expired - Fee Related
- 2013-02-09 NZ NZ628445A patent/NZ628445A/en not_active IP Right Cessation
- 2013-02-09 IN IN1548MUN2014 patent/IN2014MN01548A/en unknown
- 2013-02-09 KR KR20147023151A patent/KR20140129034A/ko not_active Withdrawn
- 2013-02-09 WO PCT/IB2013/051077 patent/WO2013118102A1/en not_active Ceased
- 2013-02-09 BR BR112014019584A patent/BR112014019584A8/pt active Search and Examination
- 2013-02-09 MX MX2014009546A patent/MX2014009546A/es unknown
- 2013-02-09 AU AU2013217229A patent/AU2013217229B2/en not_active Expired - Fee Related
- 2013-02-09 CA CA2862330A patent/CA2862330A1/en not_active Abandoned
-
2014
- 2014-07-25 ZA ZA2014/05490A patent/ZA201405490B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN104136433A (zh) | 2014-11-05 |
| EP2812327A1 (de) | 2014-12-17 |
| NZ628515A (en) | 2016-06-24 |
| EP2812326A1 (de) | 2014-12-17 |
| US9073943B2 (en) | 2015-07-07 |
| BR112014019584A8 (pt) | 2017-07-11 |
| AU2013217224A1 (en) | 2014-08-21 |
| MX2014009546A (es) | 2015-10-29 |
| CA2862755A1 (en) | 2013-08-15 |
| JP6034883B2 (ja) | 2016-11-30 |
| SG11201404475TA (en) | 2014-08-28 |
| SG11201404365SA (en) | 2014-10-30 |
| JP2015510512A (ja) | 2015-04-09 |
| BR112014019584A2 (de) | 2017-06-20 |
| AU2013217229B2 (en) | 2017-03-02 |
| US9073942B2 (en) | 2015-07-07 |
| NZ628445A (en) | 2016-05-27 |
| ZA201405490B (en) | 2015-10-28 |
| AU2013217224B2 (en) | 2017-04-06 |
| AU2013217229A1 (en) | 2014-08-21 |
| CA2862330A1 (en) | 2013-08-15 |
| WO2013118102A1 (en) | 2013-08-15 |
| WO2013118097A1 (en) | 2013-08-15 |
| KR20140129034A (ko) | 2014-11-06 |
| US20150010505A1 (en) | 2015-01-08 |
| US20150010504A1 (en) | 2015-01-08 |
| IN2014MN01548A (de) | 2015-05-08 |
| CN104136433B (zh) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01548A (de) | ||
| AU2018256602A1 (en) | Functionalized benzamide derivatives as antiviral agents against hbv infection | |
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
| NZ703040A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| NZ703064A (en) | Inhibitors of hepatitis c virus | |
| PH12014502739A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| NZ703066A (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| MX2022013596A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
| TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
| MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
| EP2555622A4 (de) | Hemmer des hepatitis-c-virus | |
| MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
| IN2012DN01855A (de) | ||
| PH12015501560A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
| PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| CA2753382C (en) | Hepatitis c virus inhibitors | |
| WO2013059278A3 (en) | Hepatitis c virus inhibitors | |
| WO2014116772A3 (en) | Squaric derivatives for the treatment of hepatitis c | |
| HK1198387A1 (zh) | 用作黃病毒科病毒抑制物之噻吩-2-羧酸衍生物 |